RADIOPHARM THERANOSTICS LIMITED - Announcements

8.82%

3.1¢

Market Cap $73.31M

Healthcare Biotechnology

Radiopharm Theranostics Limited is an Australia-based clinical-stage radiotherapeutics... Radiopharm Theranostics Limited is an Australia-based clinical-stage radiotherapeutics company developing a platform of radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. The Company has a pipeline of highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumor cancers including lung, breast, and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, and PTPu. Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate which utilizes the early steps of fatty acid oxidation.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

RAD	Corporate Governance Statement and Appendix 4G		17/09/25	1.01MB	Share
RAD	Annual Report and Form 20-F		17/09/25	2.95MB	Share
RAD	Pivalate (Brain Mets) key opinion leader webinar		15/09/25	109.29KB	Share
RAD	Appendix 4E and Preliminary Final Report	PRICE SENSITIVE	29/08/25	1.28MB	Share
RAD	Radiopharm to host key opinion leader webinar series		21/08/25	139.3KB	Share
RAD	Notification regarding unquoted securities - RAD		01/08/25	16.43KB	Share
RAD	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/07/25	5.5MB	Share
RAD	RAD receives IND approval from US FDA for Betabart (RV-01)	PRICE SENSITIVE	28/07/25	104.38KB	Share
RAD	Dr Oliver Sartor appointed to RAD Scientific Advisory Board		22/07/25	101.44KB	Share
RAD	Radiopharm Receives $4.5M R&D Tax Incentive		16/07/25	85.25KB	Share
RAD	RAD and Cyclotek Sign Supply Agreement for 161Tb-KLK3-mAb		24/06/25	104.31KB	Share
RAD	Change in substantial holding		16/06/25	274.3KB	Share
RAD	Notice Under Section 708A		12/06/25	76.43KB	Share
RAD	Application for quotation of securities - RAD		12/06/25	15.91KB	Share
RAD	RAD Granted US FDA Fast Track for RAD101 Metastases Imaging	PRICE SENSITIVE	11/06/25	108.45KB	Share
RAD	Proposed issue of securities - RAD		10/06/25	14.89KB	Share
RAD	RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202	PRICE SENSITIVE	04/06/25	113.66KB	Share
RAD	RAD Reports Positive Preclinical Lu177-B7H3-mAb Data	PRICE SENSITIVE	02/06/25	265.68KB	Share
RAD	Change of Director's Interest Notice (IT)		30/05/25	212.48KB	Share
RAD	ITM and RAD Sign Supply Agreement for n.c.a. Lutetium-177		19/05/25	122.81KB	Share
RAD	Acceleration of RAD204 Phase 1 dose escalation trial	PRICE SENSITIVE	12/05/25	205.69KB	Share
RAD	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/04/25	5.63MB	Share
RAD	First patient dosed in Phase IIb imaging for Brain Mets	PRICE SENSITIVE	28/04/25	209.13KB	Share
RAD	New RAD202 data confirms positive tumor uptake	PRICE SENSITIVE	17/03/25	194.91KB	Share
RAD	Participation in Leerink, NWR healthcare conferences		13/03/25	182.9KB	Share
RAD	Update - Notification regarding unquoted securities - RAD		07/03/25	15.64KB	Share
RAD	Notification regarding unquoted securities - RAD		07/03/25	15.98KB	Share
RAD	Half Year Report and Appendix 4D 31 December 2024	PRICE SENSITIVE	28/02/25	2.43MB	Share
RAD	Notification of cessation of securities - RAD		25/02/25	13.74KB	Share
RAD	Change of Director's Interest Notice (IT)		25/02/25	180.08KB	Share
RAD	RAD to present at TD Cowen Annual Healthcare Conference		24/02/25	142.46KB	Share
RAD	Participation in B Riley Securities Radiopharma Conference		18/02/25	153.49KB	Share
RAD	Clinical trial data shows RAD 101 detects Brain Metastases	PRICE SENSITIVE	10/02/25	212.35KB	Share
RAD	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/01/25	1.49MB	Share
RAD	Change in substantial holding		23/01/25	464.99KB	Share
RAD	Change in substantial holding		22/01/25	776.43KB	Share
RAD	Notice Under Section 708A		21/01/25	123.87KB	Share
RAD	Application for quotation of securities - RAD		21/01/25	16.46KB	Share
RAD	Response to ASX Cleansing Notice Validity Letter		20/01/25	873.22KB	Share
RAD	Lantheus increases shareholding in RAD with A$8m placement	PRICE SENSITIVE	10/01/25	89.1KB	Share
RAD	Strategic Co-Development Partnership with Lantheus for Aus	PRICE SENSITIVE	30/12/24	159.85KB	Share
RAD	RAD 202 receives approval to start Phase 1 therapeutic trial	PRICE SENSITIVE	20/12/24	88.43KB	Share
RAD	Notice Under Section 708A		19/12/24	145.27KB	Share
RAD	Application for quotation of securities - RAD		19/12/24	17.64KB	Share
RAD	Response to ASX Aware Letter	PRICE SENSITIVE	19/12/24	812.59KB	Share
RAD	Notification of cessation of securities - RAD		18/12/24	14.32KB	Share
RAD	Change of Director's Interest Notices x7		18/12/24	745.66KB	Share
RAD	Notification regarding unquoted securities - RAD		18/12/24	17.84KB	Share
RAD	Application for quotation of securities - RAD		18/12/24	16.56KB	Share
RAD	Change of Director's Interest Notice PH		10/12/24	186.16KB	Share
RAD	Completion of preclinical data package for RAD 402	PRICE SENSITIVE	10/12/24	203.1KB	Share
RAD	Constitution		02/12/24	766.85KB	Share
RAD	Notification of cessation of securities - RAD		02/12/24	13.81KB	Share
RAD	Radiopharm achieves Nasdaq listing of ADS		27/11/24	205.76KB	Share
RAD	Results of Meeting		25/11/24	126.52KB	Share
RAD	Presentation to Annual General Meeting		25/11/24	627.45KB	Share
RAD	Approval received to expand RAD204 Phase 1 trial	PRICE SENSITIVE	19/11/24	183.83KB	Share
RAD	RAD 301 shows strong imaging potential in pancreatic cancer	PRICE SENSITIVE	18/11/24	263.54KB	Share
RAD	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/10/24	1.97MB	Share
RAD	Notice of Annual General Meeting		25/10/24	674.27KB	Share
RAD	Change of Director's Interest Notice - IT		23/10/24	167.28KB	Share
RAD	RAD 202 data presented at 2024 EANM Annual Meeting		23/10/24	205.37KB	Share
RAD	BAMF Health to manufacture & dose for RAD101 Phase 2b trial		21/10/24	205.23KB	Share
RAD	RAD partners with AtomVie to develop B7H3 trial doses		16/10/24	232.53KB	Share
RAD	Initial Director's Interest Notice - ND		03/10/24	227.43KB	Share
RAD	Significant progress with B7-H3 targeting radio-antibody		03/10/24	182.91KB	Share
RAD	RAD to present at JonesResearch Radiopharma Day		02/10/24	150.52KB	Share
RAD	Appointment of Noel Donnelly as Non-Executive Director		02/10/24	156.14KB	Share
RAD	ESG Report		30/09/24	419.98KB	Share
RAD	Corporate Governance Statement and Appendix 4G		30/09/24	467.09KB	Share
RAD	Annual Report		30/09/24	1.93MB	Share
RAD	RAD Launching American Depositary Receipt (ADR) Program		19/09/24	243.97KB	Share
RAD	Change of Director's Interest Notice (x6)		18/09/24	440.97KB	Share
RAD	Becoming a substantial holder (PH)		18/09/24	167.66KB	Share
RAD	Notification regarding unquoted securities - RAD		13/09/24	16.85KB	Share
RAD	Notice Under Section 708A		13/09/24	123.9KB	Share
RAD	Application for quotation of securities - RAD		13/09/24	18.9KB	Share
RAD	Appendix 4E and Preliminary Final Report	PRICE SENSITIVE	30/08/24	3.32MB	Share
RAD	Change in substantial holding		29/08/24	736.39KB	Share
RAD	Application for quotation of securities - RAD		29/08/24	16.87KB	Share
RAD	Placement Options Range of Units and Top 20 Holders		28/08/24	168.29KB	Share
RAD	Application for quotation of securities - RAD		28/08/24	19.75KB	Share
RAD	Ceasing to be a substantial holder		27/08/24	116.65KB	Share
RAD	Ceasing to be a substantial holder		27/08/24	251.03KB	Share
RAD	RAD increases ownership in Radiopharm Ventures to 75%	PRICE SENSITIVE	26/08/24	209.68KB	Share
RAD	Becoming a substantial holder		26/08/24	888.01KB	Share
RAD	Becoming a substantial holder		23/08/24	115.53KB	Share
RAD	Change in substantial holding		23/08/24	741.43KB	Share
RAD	Change in substantial holding		23/08/24	92.51KB	Share
RAD	Notice Under Section 708A		23/08/24	124.09KB	Share
RAD	Notification regarding unquoted securities - RAD		23/08/24	18.32KB	Share
RAD	Application for quotation of securities - RAD		23/08/24	16KB	Share
RAD	Notice Under Section 708A		21/08/24	124.03KB	Share
RAD	Application for quotation of securities - RAD		21/08/24	16.02KB	Share
RAD	Notice Under Section 708A		21/08/24	123.77KB	Share
RAD	Application for quotation of securities - RAD		21/08/24	16.02KB	Share
RAD	Dr Dimitris Voliotis appointed Chief Medical Officer		20/08/24	157.08KB	Share
RAD	A$70m capital raising & Lantheus investment approved at EGM		14/08/24	178.73KB	Share
RAD	Results of Extraordinary General Meeting		14/08/24	134.06KB	Share
RAD	Presentation to Extraordinary General Meeting		14/08/24	658.54KB	Share

RAD Corporate Governance Statement and Appendix 4G
17/09/25		1.01MB	Share
RAD Annual Report and Form 20-F
17/09/25		2.95MB	Share
RAD Pivalate (Brain Mets) key opinion leader webinar
15/09/25		109.29KB	Share
RAD Appendix 4E and Preliminary Final Report
29/08/25	PRICE SENSITIVE	1.28MB	Share
RAD Radiopharm to host key opinion leader webinar series
21/08/25		139.3KB	Share
RAD Notification regarding unquoted securities - RAD
01/08/25		16.43KB	Share
RAD Quarterly Activities/Appendix 4C Cash Flow Report
29/07/25	PRICE SENSITIVE	5.5MB	Share
RAD RAD receives IND approval from US FDA for Betabart (RV-01)
28/07/25	PRICE SENSITIVE	104.38KB	Share
RAD Dr Oliver Sartor appointed to RAD Scientific Advisory Board
22/07/25		101.44KB	Share
RAD Radiopharm Receives $4.5M R&D Tax Incentive
16/07/25		85.25KB	Share
RAD RAD and Cyclotek Sign Supply Agreement for 161Tb-KLK3-mAb
24/06/25		104.31KB	Share
RAD Change in substantial holding
16/06/25		274.3KB	Share
RAD Notice Under Section 708A
12/06/25		76.43KB	Share
RAD Application for quotation of securities - RAD
12/06/25		15.91KB	Share
RAD RAD Granted US FDA Fast Track for RAD101 Metastases Imaging
11/06/25	PRICE SENSITIVE	108.45KB	Share
RAD Proposed issue of securities - RAD
10/06/25		14.89KB	Share
RAD RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202
04/06/25	PRICE SENSITIVE	113.66KB	Share
RAD RAD Reports Positive Preclinical Lu177-B7H3-mAb Data
02/06/25	PRICE SENSITIVE	265.68KB	Share
RAD Change of Director's Interest Notice (IT)
30/05/25		212.48KB	Share
RAD ITM and RAD Sign Supply Agreement for n.c.a. Lutetium-177
19/05/25		122.81KB	Share
RAD Acceleration of RAD204 Phase 1 dose escalation trial
12/05/25	PRICE SENSITIVE	205.69KB	Share
RAD Quarterly Activities/Appendix 4C Cash Flow Report
29/04/25	PRICE SENSITIVE	5.63MB	Share
RAD First patient dosed in Phase IIb imaging for Brain Mets
28/04/25	PRICE SENSITIVE	209.13KB	Share
RAD New RAD202 data confirms positive tumor uptake
17/03/25	PRICE SENSITIVE	194.91KB	Share
RAD Participation in Leerink, NWR healthcare conferences
13/03/25		182.9KB	Share
RAD Update - Notification regarding unquoted securities - RAD
07/03/25		15.64KB	Share
RAD Notification regarding unquoted securities - RAD
07/03/25		15.98KB	Share
RAD Half Year Report and Appendix 4D 31 December 2024
28/02/25	PRICE SENSITIVE	2.43MB	Share
RAD Notification of cessation of securities - RAD
25/02/25		13.74KB	Share
RAD Change of Director's Interest Notice (IT)
25/02/25		180.08KB	Share
RAD RAD to present at TD Cowen Annual Healthcare Conference
24/02/25		142.46KB	Share
RAD Participation in B Riley Securities Radiopharma Conference
18/02/25		153.49KB	Share
RAD Clinical trial data shows RAD 101 detects Brain Metastases
10/02/25	PRICE SENSITIVE	212.35KB	Share
RAD Quarterly Activities/Appendix 4C Cash Flow Report
30/01/25	PRICE SENSITIVE	1.49MB	Share
RAD Change in substantial holding
23/01/25		464.99KB	Share
RAD Change in substantial holding
22/01/25		776.43KB	Share
RAD Notice Under Section 708A
21/01/25		123.87KB	Share
RAD Application for quotation of securities - RAD
21/01/25		16.46KB	Share
RAD Response to ASX Cleansing Notice Validity Letter
20/01/25		873.22KB	Share
RAD Lantheus increases shareholding in RAD with A$8m placement
10/01/25	PRICE SENSITIVE	89.1KB	Share
RAD Strategic Co-Development Partnership with Lantheus for Aus
30/12/24	PRICE SENSITIVE	159.85KB	Share
RAD RAD 202 receives approval to start Phase 1 therapeutic trial
20/12/24	PRICE SENSITIVE	88.43KB	Share
RAD Notice Under Section 708A
19/12/24		145.27KB	Share
RAD Application for quotation of securities - RAD
19/12/24		17.64KB	Share
RAD Response to ASX Aware Letter
19/12/24	PRICE SENSITIVE	812.59KB	Share
RAD Notification of cessation of securities - RAD
18/12/24		14.32KB	Share
RAD Change of Director's Interest Notices x7
18/12/24		745.66KB	Share
RAD Notification regarding unquoted securities - RAD
18/12/24		17.84KB	Share
RAD Application for quotation of securities - RAD
18/12/24		16.56KB	Share
RAD Change of Director's Interest Notice PH
10/12/24		186.16KB	Share
RAD Completion of preclinical data package for RAD 402
10/12/24	PRICE SENSITIVE	203.1KB	Share
RAD Constitution
02/12/24		766.85KB	Share
RAD Notification of cessation of securities - RAD
02/12/24		13.81KB	Share
RAD Radiopharm achieves Nasdaq listing of ADS
27/11/24		205.76KB	Share
RAD Results of Meeting
25/11/24		126.52KB	Share
RAD Presentation to Annual General Meeting
25/11/24		627.45KB	Share
RAD Approval received to expand RAD204 Phase 1 trial
19/11/24	PRICE SENSITIVE	183.83KB	Share
RAD RAD 301 shows strong imaging potential in pancreatic cancer
18/11/24	PRICE SENSITIVE	263.54KB	Share
RAD Quarterly Activities/Appendix 4C Cash Flow Report
29/10/24	PRICE SENSITIVE	1.97MB	Share
RAD Notice of Annual General Meeting
25/10/24		674.27KB	Share
RAD Change of Director's Interest Notice - IT
23/10/24		167.28KB	Share
RAD RAD 202 data presented at 2024 EANM Annual Meeting
23/10/24		205.37KB	Share
RAD BAMF Health to manufacture & dose for RAD101 Phase 2b trial
21/10/24		205.23KB	Share
RAD RAD partners with AtomVie to develop B7H3 trial doses
16/10/24		232.53KB	Share
RAD Initial Director's Interest Notice - ND
03/10/24		227.43KB	Share
RAD Significant progress with B7-H3 targeting radio-antibody
03/10/24		182.91KB	Share
RAD RAD to present at JonesResearch Radiopharma Day
02/10/24		150.52KB	Share
RAD Appointment of Noel Donnelly as Non-Executive Director
02/10/24		156.14KB	Share
RAD ESG Report
30/09/24		419.98KB	Share
RAD Corporate Governance Statement and Appendix 4G
30/09/24		467.09KB	Share
RAD Annual Report
30/09/24		1.93MB	Share
RAD RAD Launching American Depositary Receipt (ADR) Program
19/09/24		243.97KB	Share
RAD Change of Director's Interest Notice (x6)
18/09/24		440.97KB	Share
RAD Becoming a substantial holder (PH)
18/09/24		167.66KB	Share
RAD Notification regarding unquoted securities - RAD
13/09/24		16.85KB	Share
RAD Notice Under Section 708A
13/09/24		123.9KB	Share
RAD Application for quotation of securities - RAD
13/09/24		18.9KB	Share
RAD Appendix 4E and Preliminary Final Report
30/08/24	PRICE SENSITIVE	3.32MB	Share
RAD Change in substantial holding
29/08/24		736.39KB	Share
RAD Application for quotation of securities - RAD
29/08/24		16.87KB	Share
RAD Placement Options Range of Units and Top 20 Holders
28/08/24		168.29KB	Share
RAD Application for quotation of securities - RAD
28/08/24		19.75KB	Share
RAD Ceasing to be a substantial holder
27/08/24		116.65KB	Share
RAD Ceasing to be a substantial holder
27/08/24		251.03KB	Share
RAD RAD increases ownership in Radiopharm Ventures to 75%
26/08/24	PRICE SENSITIVE	209.68KB	Share
RAD Becoming a substantial holder
26/08/24		888.01KB	Share
RAD Becoming a substantial holder
23/08/24		115.53KB	Share
RAD Change in substantial holding
23/08/24		741.43KB	Share
RAD Change in substantial holding
23/08/24		92.51KB	Share
RAD Notice Under Section 708A
23/08/24		124.09KB	Share
RAD Notification regarding unquoted securities - RAD
23/08/24		18.32KB	Share
RAD Application for quotation of securities - RAD
23/08/24		16KB	Share
RAD Notice Under Section 708A
21/08/24		124.03KB	Share
RAD Application for quotation of securities - RAD
21/08/24		16.02KB	Share
RAD Notice Under Section 708A
21/08/24		123.77KB	Share
RAD Application for quotation of securities - RAD
21/08/24		16.02KB	Share
RAD Dr Dimitris Voliotis appointed Chief Medical Officer
20/08/24		157.08KB	Share
RAD A$70m capital raising & Lantheus investment approved at EGM
14/08/24		178.73KB	Share
RAD Results of Extraordinary General Meeting
14/08/24		134.06KB	Share
RAD Presentation to Extraordinary General Meeting
14/08/24		658.54KB	Share

REFRESH

1 2 3

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 3.1¢		Change -0.003(8.82%)		Mkt cap ! $73.31M

Open	High	Low	Value	Volume
3.4¢	3.4¢	3.1¢	$58.95K	1.821M

Buyers (Bids)

No.	Vol.	Price($)
4	783888	3.1¢

Sellers (Offers)

Price($)	Vol.	No.
3.2¢	870662	1

View Market Depth

No.	Vol.	Price($)
4	783888	0.031
3	1230000	0.030
6	505133	0.029
3	649718	0.028
5	1761111	0.027

Price($)	Vol.	No.
0.032	870662	1
0.033	877110	2
0.034	1290328	3
0.035	2373494	10
0.036	1165378	3

Last trade - 16.10pm 19/09/2025 (20 minute delay)


Last 3.2¢		Change -0.003 ( 5.88 %)
Open	High	Low	Volume
3.3¢	3.3¢	3.1¢	1116802
Last updated 15.13pm 19/09/2025 ?

RAD (ASX) Chart

RADIOPHARM THERANOSTICS LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available